Compounds > alpha-aminopyridine
Page last updated: 2024-08-21

alpha-aminopyridine and plx4032

alpha-aminopyridine has been researched along with plx4032 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Beckmann, RP; Buchanan, SG; Burke, TF; Chan, EM; Huber, L; Peng, SB; Starling, JJ; Van Horn, RD; Yadav, V; Zhang, Y1
Blank, C; Cornelissen-Steijger, PD; Geukes Foppen, MH; Goding, CR; Graeber, TG; Haanen, J; Hugo, W; Kemper, K; Kong, X; Krijgsman, O; Lo, RS; McDermott, U; Müller, J; Peeper, DS; Possik, PA; Ribas, A; Robert, L; Song, C; Tsoi, J1
Bollag, G; Graeber, TG; Hu-Lieskovan, S; Koya, RC; Mok, S; Ribas, A; Tsoi, J; West, BL1
Beckmann, RP; Burke, TF; Cronier, DM; Hartman, D; Kulanthaivel, P; Tate, SC1
Algazi, AP; Daud, A; Munster, PN; Ortiz-Urda, S; Pelayo, A; Posch, C; Rotow, J1
Adderley, T; Christopher, G; Irwin, MS; Kano, Y; Kee, L; Ladumor, Y; Ohh, M; Robinson, CM; Valencia-Sama, I1

Other Studies

6 other study(ies) available for alpha-aminopyridine and plx4032

ArticleYear
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:10

    Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Transfection; Up-Regulation; Vemurafenib; Xenograft Model Antitumor Assays

2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Nature communications, 2014, Dec-15, Volume: 5

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Imidazoles; Indoles; Melanoma; Mice; Microphthalmia-Associated Transcription Factor; Oximes; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays

2014
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    BMC cancer, 2015, May-05, Volume: 15

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Indoles; Lymphocyte Activation; Macrophages; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sulfonamides; T-Lymphocytes; Vemurafenib

2015
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    British journal of cancer, 2016, Mar-15, Volume: 114, Issue:6

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Models, Biological; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays

2016
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600
    Pigment cell & melanoma research, 2019, Volume: 32, Issue:4

    Topics: Aminopyridines; Disease Progression; Humans; Melanoma; Morpholines; Mutation; Proto-Oncogene Proteins B-raf; Vemurafenib

2019
    Cancer research, 2020, 08-15, Volume: 80, Issue:16

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib

2020